(5-甲基-3-苯基-4-异恶唑)甲醇 | 18718-79-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (5-甲基-3-苯基-4-异恶唑)甲醇
• 中文别名: (5-甲基-3-苯基异噁唑-4-基)甲醇；5-甲基-4-羟甲基-3-苯基异噻唑
• 英文名称: 5-methyl-3-phenyl-4-isoxazolylmethanol
• 英文别名: (5-methyl-3-phenylisoxazol-4-yl)methanol；(5-Methyl-3-phenyl-1,2-oxazol-4-yl)methanol
• CAS: 18718-79-1
• 化学式: C₁₁H₁₁NO₂
• mdl: MFCD02677724
• 分子量: 189.214
• InChiKey: GHGWDZCXZRWQBG-UHFFFAOYSA-N

物化性质

• 熔点：
  81 °C
• 沸点：
  382.4±30.0 °C(Predicted)
• 密度：
  1.176±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39
• 储存条件：
  室温

SDS

Name:	(5-Methyl-3-phenyl-4-isoxazolyl)methanol 97% Material Safety Data Sheet
Synonym:	4-Hydroxymethyl-5-methyl-3-phenylisoxazol
CAS:	18718-79-1

Section 1 - Chemical Product MSDS Name:(5-Methyl-3-phenyl-4-isoxazolyl)methanol 97% Material Safety Data Sheet
Synonym:4-Hydroxymethyl-5-methyl-3-phenylisoxazol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18718-79-1	(5-Methyl-3-phenyl-4-isoxazolyl)methan	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 18718-79-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 81 - 83 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H11NO2
Molecular Weight: 189

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases, acids, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18718-79-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(5-Methyl-3-phenyl-4-isoxazolyl)methanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 18718-79-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 18718-79-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18718-79-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (5-甲基-3-苯基-4-异恶唑)甲醇 在 ammonium hydroxide 、 magnesium sulfate 、 pyridinium chlorochromate 作用下， 以 甲醇 、 二氯甲烷 、 苯 为溶剂， 反应 2.0h， 生成 NSC 375974
  参考文献：
  名称：

  Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter

  摘要：

  A series of dimeric isoxazolyl-1,4-dihydropyridines (IDHPs) were prepared by click chemistry and examined for their ability to bind the multi-drug resistance transporter (MDR-1), a member of the ATP-binding cassette superfamily (ABC). Eight compounds in the present study exhibited single digit micromolar binding to this efflux transporter. One monomeric IDHP m-Br-1c, possessed submicromolar binding of 510 nM at MDR-1. Three of the dimeric IDHPs possessed <1.5 mu M activity, and 4b and 4c were observed to have superior binding selectivity compared to their corresponding monomers verses the voltage gated calcium channel (VGCC). The dimer with the best combination of activity and selectivity for MDR-1 was analog 4c containing an m-Br phenyl moiety in the 3-position of the isoxazole, and a tether with five ethyleneoxy units, referred to herein as Isoxaquidar. Two important controls, mono-triazole 5 and pyridine 6, also were examined, indicating that the triazole - incorporated as part of the click assembly as a spacer - contributes to MDR-1 binding. Compounds were also assayed at the allosteric site of the mGluR5 receptor, as a GPCR 7TM control, indicating that the p-Br IDHPs 4d, 4e and 4f with tethers of from n = 2 to 5 ethylenedioxy units, had sub-micromolar affinities with 4d being the most efficacious at 193 nM at mGluR5. The results are interpreted using a docking study using a human ABC as our current working hypothesis, and suggest that the distinct SARs emerging for these three divergent classes of biomolecular targets may be tunable, and amenable to the development of further selectivity. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.04.008
• 作为产物：
  描述：

  苯甲醛肟 在 aluminum oxide 、 N-氯代丁二酰亚胺 、 硼烷四氢呋喃络合物 、 水 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 生成 (5-甲基-3-苯基-4-异恶唑)甲醇
  参考文献：
  名称：

  手性巯基乙酰胺在氧化应激的皮质神经元模型中显示组蛋白去乙酰化酶6的对映体选择性抑制和展示神经保护作用。

  摘要：

  基于巯基乙酰胺的配体已被设计为新型的组蛋白脱乙酰基酶（HDAC）抑制剂，可用于治疗神经退行性疾病。这些化合物的硫醇基团提供了与催化锌离子相互作用的关键结合元素，因此不同于更常用的基于异羟肟酸的锌结合基团。本文中，我们公开了一些取代的巯基乙酰胺的化学和生物学性质，目的是提高HDAC6同工型的选择性，同时保持类似于其异羟肟酸类似物的效价。发现向硫醇基团引入立体中心α对HDAC抑制剂效能具有相当大的影响。

  DOI：

  10.1002/cmdc.201100522

文献信息

• [EN] ISOXAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOXAZOLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010125042A1

  公开（公告）日：2010-11-04

  The present invention is concerned with novel isoxazole derivatives of formula (I), wherein X, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as medicaments.

  本发明涉及式(I)的新异噁唑衍生物，其中X、R1、R2、R3、R4和R5如本文所述，以及其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外，本发明涉及制备式I的活性化合物、含有它们的药物组合物以及它们作为药物的用途。
• [EN] ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS<br/>[FR] DÉRIVÉS D'ISOXAZOLE-THIAZOLE COMME AGONISTES INVERSES DU RÉCEPTEUR GABA A, UTILES DANS LE TRAITEMENT DE TROUBLES COGNITIFS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010127974A1

  公开（公告）日：2010-11-11

  The present invention is concerned with isoxazole-thiazole derivatives of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.

  本发明涉及式I的异恶唑-噻唑衍生物，具有对GABA A α5受体的亲和力和选择性，其制备、含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物可用作认知增强剂或用于治疗和/或预防认知障碍，如阿尔茨海默病。
• Novel piperazine derivatives
  申请人：——

  公开号：US20020143020A1

  公开（公告）日：2002-10-03

  The present invention is a chemical compound of formula (I) 1 or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R 1 to R 4 , A 1 , A 2 m and n are as described in the specification.

  本发明是一种具有公式(I)的化学化合物 1 或其药物可接受的盐、溶剂化物和酯，其中R 1 至R 4 ，A 1 ，A 2 ，m和n如说明书中所述。
• ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES
  申请人：Hernandez Maria-Clemencia

  公开号：US20100210651A1

  公开（公告）日：2010-08-19

  The present invention is concerned with isoxazole-isoxazoles and isoxazole-isothiazoles of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.

  本发明涉及具有亲和力和选择性作用于GABA A α5受体的式I的异噁唑-异噁唑和异噁唑-异硫唑化合物，其制备方法，含有它们的药物组合物以及它们作为认知增强剂或用于治疗和/或预防认知障碍如阿尔茨海默病的用途。
• [EN] ISOXAZOLE-PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOXAZOLE-PYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010127976A1

  公开（公告）日：2010-11-11

  The present invention is concerned with isoxazole-pyridine derivatives of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.

  本发明涉及式I的异恶唑-吡啶衍生物，具有对GABA A α5受体的亲和力和选择性，其制备、含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物可用作认知增强剂，或用于治疗和/或预防认知障碍，如阿尔茨海默病。